Abstract
Cancer immunology and immunotherapy are driving forces of research and development in oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent progress highlights the importance of CD4+ T cells, corresponding to the long-known fact that CD4+ T cells are central players and coordinators of innate and antigen-specific immune responses. Moreover, they have now been recognized as anti-tumor effector cells in their own right. Here we review the current status of CD4+ T cells in cancer, which hold great promise for improving knowledge and therapies in cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 317-329 |
| Number of pages | 13 |
| Journal | Nature Cancer |
| Volume | 4 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2023 |
| Externally published | Yes |